R&D Why VCs fell in love with pharma R&D in 2021 For many years, those inside the pharma industry have been telling the same old story about innovation: pharma is big, slow, and risk averse. Start-ups move fast and break things.
Views & Analysis US loses, EU wins as Chinese biotech investment shifts focus Chinese biotech investors are taking an interest in the European market as diplomatic relations with the US become strained.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face